The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
64Cu-DOTA-trastuzumab-PET imaging in patients with HER2-positive breast cancer.
Kenji Tamura
No relevant relationships to disclose
Hiroaki Kurihara
No relevant relationships to disclose
Kan Yonemori
No relevant relationships to disclose
Kazuhiro Takahashi
No relevant relationships to disclose
Yasuhiro Wada
No relevant relationships to disclose
Koki Hasegawa
No relevant relationships to disclose
Fumiaki Koizumi
No relevant relationships to disclose
Hitoshi Tsuda
No relevant relationships to disclose
Makoto Kodaira
No relevant relationships to disclose
Mayu Yunokawa
No relevant relationships to disclose
Chikako Shimizu
No relevant relationships to disclose
Masashi Ando
No relevant relationships to disclose
Yasuyoshi Watanabe
No relevant relationships to disclose
Yasuhiro Fujiwara
No relevant relationships to disclose